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Background: Hepatitis B and C are major public health threats in the World Health Organization (WHO) European
Region. Viral hepatitis surveillance shortcomings have resulted in many WHO Member States having insufficient
data available to guide decision-making. This study describes surveillance in the region based on a quantitative
sub-analysis of findings from the 2013 WHO viral hepatitis policy report and a qualitative analysis of civil society
survey responses associated with these findings.
Methods: Descriptive statistics were created from information that national government focal points for viral hepatitis
in 44 countries had previously reported in response to the WHO survey. Bivariate analysis was performed to compare
data from within and outside of the European Union/European Economic Area (EU/EEA). Survey responses from civil
society organizations in the countries of the WHO European Region were collated, and a descriptive analysis of the
comments on surveillance-related questions was performed to identify key themes.
Results: The response rate for the survey of governments was 83 % among both EU/EEA countries (25/30) and
non-EU/EEA countries (19/23). More than 90 % of governments reported having national surveillance systems for
the acute forms of hepatitis B and hepatitis C, but less than two-thirds reported surveillance for the chronic forms
of both diseases. High proportions of governments reported having central registries for the reporting of deaths
(96 %) and liver cancer cases (80 %), while less than half reported regularly conducting viral hepatitis sero-surveys.
All responding Member States reported having adequate laboratory capacity nationally to support hepatitis outbreak
investigations and other surveillance activities. Target populations for sero-surveys most commonly included people
who inject drugs (27 %), the general population (25 %), men who have sex with men (20 %) and pregnant women
(20 %). Few statistically significant differences were found between EU/EEA and non-EU/EEA countries.
Conclusions: Study findings indicated a capacity for robust viral hepatitis surveillance across the WHO European Region,
with most countries having important surveillance components in place, but notable weaknesses were also identified.
There is an urgent need for countries throughout the region to strengthen their surveillance programs in order to
maximize the population-level impact of advances in HBV and HCV prevention and treatment.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV) are
increasingly recognized as major public health threats
worldwide. These two viruses are estimated to cause
approximately 1.4 million deaths annually [1]. An esti-
mated 57 % of liver cirrhosis cases and 78 % of primary
liver cancer cases are attributable to HBV and HCV in-
fections [2]. In the World Health Organization (WHO)
European Region, more than 18 million adults are esti-
mated to be carrying the hepatitis B surface antigen
(HBsAg) [3], which is a marker of chronic HBV infec-
tion. An estimated 15 million adults in this region have
HCV-RNA [3], which is a marker of HCV infection.
Two-thirds of HBsAg-positive people and HCV-RNA-
positive people live in the countries outside of the
European Union (EU) and European Free Trade Associ-
ation (EFTA), even though those countries account for
only 42 % of the WHO European Region’s adult popu-
lation [3]. Throughout the Region, high levels of HCV
transmission, and to a lesser extent, HBV transmission,
are known to occur through injecting drug use [4].
Eighty percent of new HCV infections with a known
transmission route in EU and European Economic As-
sociation (EEA) countries are attributable to injecting
drug use [5]. Regarding HBV, additional transmission
pathways of note in the region are heterosexual sex and
sex between men. In some European countries, nosoco-
mial transmission of HBV also contributes to the disease
burden. Available epidemiological evidence on HBV and
HCV among migrants suggests that many migrant groups
are also disproportionately affected in several European
countries [3, 6, 7].
Major advances in the prevention and treatment of
chronic HBV and HCV infections are influencing the
course of both epidemics. An effective hepatitis B vaccine
became available in 1982, and the mass immunization
campaigns that followed led to a sharp decline in new
infections. For example, a recent study in Tajikistan
demonstrated seven-fold lower prevalence of HBsAg
among the vaccinated birth cohorts compared with the
baseline among unvaccinated cohorts [8]. The strategy of
providing the first dose of HBV vaccine within 24 h of
birth is effective for preventing mother-to-child HBV
transmission and may ultimately help to bring about the
eradication of the virus [9]. In the last decade, treatment
options for chronic HBV and HCV infection have dramat-
ically improved, resulting in better short-term and long-
term survival as well as better quality of life for people
with these diseases. Effective antiviral agents can supress
replication of the hepatitis B virus in most infected people
[10], and recent HCV treatment breakthroughs have made
it possible to cure chronic HCV infection in more than
90 % of patients [11]. Consequently, people with access to
HBV and HCV treatment can greatly reduce their risk ofdeveloping cirrhosis, liver cancer and liver failure [10,
12]. In light of the potential impact of these develop-
ments, combined with other essential prevention inter-
ventions, WHO has made the elimination of viral
hepatitis as a public health threat by 2030 the overarch-
ing goal of its ambitious first-ever global health sector
strategy on viral hepatitis [13].
In order to take full advantage of advances in viral
hepatitis prevention, treatment and care, decision-makers
need to work from a strong evidence base that includes
accurate surveillance data [14, 15]. Case reporting, based
on regular notification by clinicians and laboratories,
has traditionally been the foundation of viral hepatitis
surveillance. At the same time, other information sources
aimed at assessing disease burden and outcomes, such as
serological surveys and cancer and death registries, are
important for measuring the impact of hepatitis infections
and evaluating the efficacy of interventions [14]. The im-
portance of reliable information gathered through epi-
demiological surveillance was recognized by the World
Health Assembly in its 2010 resolution on viral hepatitis
[16]. Four years later, in a second viral hepatitis resolution,
the World Health Assembly noted that “most Member
States lack adequate surveillance systems for viral hepa-
titis to enable them to take evidence-based policy
decisions” and repeated its 2010 call for Member States
(MS) to remedy this situation [17]. The new resolution
also called on MS to develop and implement national
viral hepatitis strategies “based on the local epidemio-
logical context,” further calling attention to the need for
robust surveillance. WHO has provided technical support
to MS by publishing in February 2016 its first comprehen-
sive viral hepatitis surveillance guidance [18] and in April
2016, a monitoring and evaluation framework for the
global health sector strategy on viral hepatitis [19].
In recent years, the European Centre for Disease
Prevention and Control (ECDC) has led efforts to
improve and harmonize viral hepatitis surveillance in
the 28 EU MS, along with three EEA countries (Iceland,
Liechtenstein and Norway). A key ECDC accomplish-
ment has been the introduction of an enhanced hepatitis
B and C surveillance program, which calls for EU/EEA
countries to provide case-based data using standardized
case definitions to the European Surveillance System
(TESSy), a web-based data management platform [20].
Two 2015 publications indicated that, while the program
has brought about considerable improvements to the
quality of the data collected, some aspects of viral hepa-
titis surveillance, such as the completeness of the data
and the task of classifying cases as acute or chronic,
remain challenging. Furthermore, the current EU case
definitions have yet to be adopted in all countries, which
makes it difficult to compare data among countries
[21, 22].
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undertaken in the non-EU/EEA countries. Publications
documenting viral hepatitis surveillance practices in
non-EU/EEA countries are scarce. The purpose of this
study is to describe HBV and HCV surveillance policies
and practices across the entire WHO European region
based on a sub-analysis of surveillance-related findings
from the WHO global viral hepatitis policy survey [23]
and to present complementary qualitative findings from
a civil society survey [24].Methods
We carried out the following study using two existing
datasets.WHO global viral hepatitis policy survey
WHO, in collaboration with the World Hepatitis Alli-
ance and the University of Copenhagen, conducted a
survey of national policy responses to viral hepatitis
among its 194 MS between 2012 and 2013. Findings
were published in July 2013 in the Global Policy Report
on the Prevention and Control of Viral Hepatitis in
WHO Member States [23]. The quantitative data ana-
lyzed in this article are drawn from this survey. The data
collection process for the survey is described in detail in
Annex D of the report. In brief, a survey tool (Additional
file 1) was developed for the purpose of collecting infor-
mation about how national governments are addressing
various aspects of viral hepatitis, including surveillance.
After being piloted in 13 MS, it was distributed to all
MS worldwide. In each MS, the national government
focal point for viral hepatitis was asked to complete the
survey. Data collection took place between July 2012
and February 2013. A total of 126 MS responded to the
survey (65 %).
This article analyzes the data collected from the WHO
European Region MS that participated in the survey. Re-
sponses were extracted for 18 questions pertaining to
viral hepatitis surveillance; collection and use of other
strategic information such as registries for death, liver
cancer and HIV/hepatitis co-infection; viral hepatitis
serosurveys; and screening of blood donors and pregnant
women. We performed a descriptive analysis of all
responses in accordance with the WHO European Region’s
geographical divisions for its 53 MS (West, Centre and
East), as well as a comparison between EU/EEA countries
and non-EU/EEA countries.
EU/EEA membership was determined in accordance
with member status at the end of 2013. Thirty MS were
defined as EU/EEA countries, including Croatia, which
was in the process of joining the EU at that time. Lich-
tenstein was excluded since it is not a WHO MS.
Twenty-three WHO MS were non-EU/EEA countries.Basic statistical analysis of the data was undertaken
and differences between the EU/EEA and non-EU/EEA
regions were analyzed using the Chi-squared test. Bi-
variate analyses were two-tailed with a significance
level of 0.05. All analyses were carried out using IBM
SPSS version 20.0 software (Armonk, NY, USA).
Community hepatitis policy survey
In 2014, the World Hepatitis Alliance followed up the
WHO policy survey with a global community hepatitis pol-
icy survey designed to give stakeholders outside of govern-
ment the opportunity to share their perspectives. This
survey, which was carried out by the University of
Copenhagen, asked civil society organizations and
community-based organizations, including patient groups,
to assess the accuracy of their governments’ responses to
the earlier WHO survey (Additional file 2). Respondents
were also invited to comment further on hepatitis policy is-
sues in their countries. Findings were published in July
2014 in the Global Community Hepatitis Policy Report [24].
This survey was written in English, and responses were
sought from World Hepatitis Alliance members (patient
groups) as well as other non-governmental organizations
(NGOs), academic institutions and medical associations.
The survey was distributed via e-mail to approximately
800 organizations worldwide identified by the World
Hepatitis Alliance and the University of Copenhagen, in-
cluding 253 organizations in the WHO European Region.
Data collection took place between February 1, 2014 and
June 15, 2014.
The first part of the survey requested information about
the responding organization. The second part asked each
respondent to review 25 items of information provided by
the respondent’s country to the WHO survey, and to indi-
cate whether he or she considered this information to be
accurate. Respondents could also provide comments
about each item. In the third part of the survey, respon-
dents were invited to write statements about key national
hepatitis policy issues of their choosing. Civil society
stakeholders in countries where governments had not
provided information to WHO were invited to complete a
different survey that asked them to write statements about
key national hepatitis policy issues of their choosing.
Responses from civil society organizations in the coun-
tries of the WHO European Region were collated for
this study, and a descriptive analysis of the comments
on surveillance-related questions was performed to
identify key themes.
Results
WHO hepatitis policy survey
Respondents
Forty-four (83 %) of the 53 MS in the WHO European
Region replied to the survey and were included in the
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MS in the West responded (78 %), as did 13 of the 15
MS in the Centre (87 %) and 13 of the 15 MS in the
East (87 %). The response rate was 83 % among both
EU/EEA countries (25/30) and non-EU/EEA countries
(19/23) (Fig. 1).
Descriptive findings
National coordination and routine surveillance
Thirteen responding MS (30 %) reported having a writ-
ten national prevention and control strategy or plan for
viral hepatitis: 5 (28 %) in the West, 3 (23 %) in the
Centre and 5 (39 %) in the East. Twelve of those 13 MS
(92 %) indicated that this strategy included a surveillance
component (Table 1; Additional file 3). Ninety-eight per-
cent of responding MS reported having national surveil-
lance systems for acute hepatitis B, and 93 % for acute
hepatitis C. Sixty-five percent of MS reported having a
surveillance system for chronic hepatitis B, and 61 % for
chronic hepatitis C. Ninety-six percent of MS reported
having standard case definitions for viral hepatitis
infections. Twenty-three percent responded that no
viral hepatitis infections were reported to the nationalFig. 1 Geographical/epidemiological divisions of the WHO European Regiosurveillance system as “undifferentiated” or “unclassified.”
All responding MS reported having adequate laboratory
capacity nationally to support hepatitis outbreak investi-
gations and other surveillance activities for HBV and
HBC. Finally, 89 % of responding MS reported that viral
hepatitis disease reports were published at least once a
year (Table 2; Additional file 4).
Other sources of strategic information and capacities
for disease burden estimation Ninety-six percent of
MS responding to the survey reported having central
registries for the reporting of deaths, including deaths
related to viral hepatitis, and 80 % for the reporting of
liver cancer cases. Sixty-six percent reported having na-
tional HIV/viral hepatitis co-infection registries. A total of
20 MS (46 %) reported undertaking viral hepatitis sero-
surveys regularly. Target populations for sero-surveys
most commonly included people who inject drugs (27 %),
the general population (25 %), men who have sex with
men (20 %) and pregnant women (20 %). Universal HBV
screening for pregnant women was reported to take place
in 77 % of responding MS. All countries with blood
transfusion services reported screening all donated bloodn
Table 1 Reporting by Member States on the existence of a written national viral hepatitis strategy or plan
World Health Organization European sub-region Total
West Centre East
N = 18 (%) N = 13 (%) N = 13 (%) N = 44 (%)
Existence of a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis:
yes 5 (27.8) 3 (23.1) 5 (38.5) 13 (29.6)
no 13 (78.2) 10 (76.9) 8 (61.5) 31 (70.5)
If there is a strategy or plan, does it include a surveillance component?
N = 5 (%) N = 3 (%) N = 5 (%) N = 13 (%)
yes 5 (100) 3 (100) 4 (80.0) 12 (92.3)
no 0 (0) 0 (0) 1 (20.0) 1 (7.7)
If there is a strategy or plan, is it exclusive for viral hepatitis or does it also address other diseases?
N = 5 (%) N = 3 (%) N = 5 (%) N = 13 (%)
exclusive for viral hepatitis 1 (20.0) 1 (33.3) 2 (40.0) 4 (30.8)
only for HBV 0 (0) 1 (33.3) 0 (0) 1 (7.7)
only for HCV 1 (20.0) 0 (0) 0 (0) 1 (7.7)
integrated with other diseases 3 (60.0) 1 (33.3) 3 (60.0) 7 (53.8)
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screening for HBV infection (Table 3; Additional file 5).
Areas in which Member States might want assistance
from WHO Seventeen responding MS (39 %) indicated
that they might want assistance from WHO in develop-
ing national viral hepatitis prevention and control plans,
with the majority (n = 10; 77 %) of those MS located in
the East. Ten countries (23 %) expressed interest in re-
ceiving WHO assistance with viral hepatitis surveillance,
and 15 countries (34 %) did likewise for estimating the
national burden of viral hepatitis. Again, much of the
interest in receiving assistance came from the East, with
eight MS (62 %) providing this response to both survey
items (Table 4; Additional file 6).
Differences in survey findings between EU/EEA and
non-EU/EEA member states
With regard to routine surveillance, slightly more coun-
tries in the EU/EEA than in non-EU/EEA MS reported
conducting surveillance for chronic hepatitis, and all
EU/EEA countries had standard case definitions, but
these differences were not statistically significant. There
were also non-significant differences regarding liver can-
cer registries and central death registries, with slightly
more EU/EEA MS reporting that both were in place in
their countries. Statistically significant differences oc-
curred for only two survey items. More non-EU/EEA
countries expressed interest in two forms of assistance
from WHO: assistance developing national plans for
viral hepatitis prevention and control (58 % versus 24 %,
p = 0.024); and assistance with surveillance (42 % versus
8 %, p = 0.010) (Table 5).Global community hepatitis policy survey
Forty organizations from 27 countries in the WHO Euro-
pean Region responded to the World Hepatitis Alliance’s
global community policy survey. Fifteen organizations
(38 %) identified themselves as hepatitis patient groups and
another seven (18 %) identified themselves as NGO direct
service providers. Other types of organizations included
other types of NGOs as well as medical societies and
private foundations. Twenty-three of these countries (12
from the countries outside of the EU/EEA) had responded
to the 2013 WHO global policy survey, and thus, the 35
respondents based in those countries were able to com-
ment on the accuracy of their governments’ responses.
In their comments, a number of respondents disputed
or questioned the information that their governments had
reported to WHO about surveillance policies and prac-
tices. Areas of disagreement related to the existence of
routine viral hepatitis surveillance, the registration of liver
cancer cases and cases of HIV/hepatitis co-infection, and
the publication of hepatitis disease reports.
There is definitely no national registry for hepatocellular
cancer. The information provided [for the WHO survey]
is a misunderstanding, because it looks like the
government representative who completed the survey
confused the voluntary reporting system that exists in
Poland with a register which contains all crucial data
about particular patients. Of course data on
hepatocellular carcinoma and hepatitis patients are
collected by the National Health Fund but they are not
analyzed and not provided upon the request of medical
societies or even pharmaco-economic agencies. –
Polish Association for the Study of the Liver (Poland)
Table 2 Reporting by Member States on routine surveillance of viral hepatitis B and C
World Health Organization European sub-region Total
West Centre East
N = 18 (%) N = 13 (%) N = 13 (%) N = 44 (%)
National surveillance system for acute HBV:
yes 17 (94.4) 13 (100) 13 (100) 43 (97.3)
no 1 (5.6) 0 (0) 0 (0) 1 (2.3)
National surveillance system for acute HCV:
yes 15 (83.3) 13 (100) 13 (100) 41 (93.2)
no 3 (16.7) 0 (0) 0 (0) 3 (6.8)
National surveillance system for chronic HBV:
yes 11 (61.1) 7 (53.8) 10 (76.9) 28 (63.6)
no 7 (38.9) 6 (46.2) 3 (23.1) 16 (36.4)
National surveillance system for chronic HCV:
yes 10 (55.6) 7 (53.8) 10 (76.9) 27 (61.4)
no 8 (44.4) 6 (46.2) 3 (23.1) 17 (38.6)
Standard case definitions for viral hepatitis infections:
yes 17 (94.4) 13 (100) 12 (92.3) 42 (95.5)
no 1 (5.6) 0 (0) 1 (7.7) 2 (4.5)
% of hepatitis cases reported as “undifferentiated” or “unclassified”:
zero 6 (33.3) 2 (15.4) 2 (15.4) 10 (22.7)
less than 5 % 2 (11.1) 4 (30.8) 3 (23.1) 9 (20.5)
5–15 % 0 (0) 2 (15.4) 3 (23.1) 5 (11.4)
more than 15 % 1 (5.6) 2 (15.4) 1 (7.1) 4 (9.1)
no response 9 (50.0) 3 (23.1) 4 (30.8) 16 (36.4)
Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other surveillance activities for HBV and HBC:
yes 18 (100) 13 (100) 13 (100) 44 (100)
Hepatitis outbreaks required to be reported to the government and further investigated:
yes 17 (94.4) 13 (100) 12 (92.3) 42 (95.5)
no 1 (5.6) 0 (0) 1 (7.7) 2 (4.5)
Hepatitis disease reports published regularly (at least once per year):
yes 15 (83.3) 13 (100) 11 (84.6) 39 (88.6)
no 3 (16.7) 0 (0) 2 (15.4) 5 (11.4)
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government. Very curious to [know what the survey
submitted to WHO] means regarding a “hepatitis
disease report.” – Associazione EpaC (Italy)
Additionally, some respondents indicated that, although
their governments had reported having surveillance sys-
tems in place, the systems did not function adequately
with regard to distinguishing between acute and chronic
viral hepatitis or capturing other important information.
There is an inefficient [surveillance] system, which
has been improved recently by shifting the reportingfrom the physicians to the virology laboratories.
However, there is no information available on the
clinical scenario, and no distinction is possible
between acute and chronic hepatitis. Also, this is
not routine surveillance in a strict sense but just
opportunistic surveillance, finding cases by chance if
the treating physician decides to order a test. –
Österreichische Gesellschaft für Gastroenterologie
und Hepatologie (Austria)
This is a misunderstanding. Government recognizes as
a “surveillance system” the voluntary reporting of
hepatitis cases by physicians. So this is a passive
Table 3 Reporting by Member States on other sources of strategic information and capacities for disease burden estimation
World Health Organization European sub-region Total
West Centre East
N = 18 (%) N = 13 (%) N = 13 (%) N = 44 (%)
Deaths, including from hepatitis, reported to a central registry:
yes 17 (94.4) 13 (100) 12 (92.3) 42 (95.5)
no 1 (5.6) 0 (0) 0 (0) 1 (2.3)
no response 0 (0) 0 (0) 1 (7.7) 1 (2.3)
Liver cancer cases registered nationally:
yes 15 (83.3) 11 (84.6) 9 (69.2) 35 (79.5)
no 3 (16.7) 2 (15.4) 3 (23.1) 8 (18.2)
do not know 0 (0) 0 (0) 1 (7.7) 1 (2.3)
Cases of HIV/hepatitis co-infection registered nationally:
yes 10 (55.6) 10 (76.9) 9 (69.2) 29 (65.9)
no 8 (44.4) 3 (23.1) 4 (30.8) 15 (34.1)
Viral hepatitis serosurveys conducted regularly:
yes 8 (44.4) 5 (38.5) 7 (53.8) 20 (45.5)
no 10 (55.6) 6 (46.2) 6 (46.2) 22 (50.0)
do not know 0 (0) 2 (15.4) 0 (0) 2 (4.5)
Target populations for serosurveys (respondents were given the options of “children”, “general population”, “people who inject drugs”,
“men who have sex with men”, and “other groups”, with space for identifying other groups):
children 2 (11.1) 1 (7.7) 2 (15.4) 5 (11.4)
general population 4 (22.2) 5 (38.5) 2 (15.4) 11 (25.0)
people who inject drugs 4 (22.2) 3 (23.1) 5 (38.5) 12 (27.3)
men who have sex with men 2 (11.1) 4 (30.8) 3 (23.1) 9 (20.5)
pregnant women 2 (11.1) 2 (15.4) 5 (38.5) 9 (20.5)
prisoners 2 (11.1) 2 (15.4) 2 (15.4) 6 (13.6)
health care workers 0 (0) 2 (15.4) 4 (30.8) 6 (13.6)
sex workers 1 (5.6) 2 (15.4) 2 (15.4) 5 (11.4)
people living with HIV 0 (0) 1 (7.7) 2 (15.4) 3 (6.8)
blood donors 0 (0) 1 (7.7) 3 (23.1) 4 (9.1)
military 0 (0) 0 (0) 2 (15.4) 2 (4.5)
Roma youth 0 (0) 1 (7.7) 0 (0) 1 (2.3)
All pregnant women screened for HBV:
yes 16 (88.9) 9 (69.2) 9 (69.2) 34 (77.3)
no 2 (11.1) 4 (30.8) 4 (30.8) 10 (22.7)
All donated blood (including family donations) screened for HBV:
Yes 17 (94.4) 13 (100) 12 (100) 42 (95.5)
no 0 (0) 0 (0) 1 (7.7) 1 (2.3)
N/A (no blood centres) 1 (5.6) 0 (0) 0 (0) 1 (2.3)
All donated blood (including family donations) screened for HCV:
yes 17 (94.4) 13 (100) 13 (100) 43 (97.7)
N/A (no blood centres) 1 (5.6) 0 (0) 0 (0) 1 (2.3)
Lazarus et al. Hepatology, Medicine and Policy  (2016) 1:3 Page 7 of 13system. There is no active surveillance program based
on the screening of high-risk populations. … The data
collected by the National Institute of Health –recognized as a surveillance system – provides just a
reporting rate and not a prevalence rate. – Polish
Association for the Study of the Liver (Poland)
Table 4 Reporting by Member States regarding areas in which they might want assistance from WHO
World Health Organization European sub-region Total
West Centre East
N = 18 (%) N = 13 (%) N = 13 (%) N = 44 (%)
Areas in which government might want WHO assistance:
national plan 2 (11.1) 5 (38.5) 10 (76.9) 17 (38.6)
surveillance 1 (5.6) 1 (7.7) 8 (61.5) 10 (22.7)
burden estimation 1 (5.6) 6 (46.2) 8 (61.5) 15 (34.1)
Table 5 Member States of the WHO European region reporting on surveillance-related activities by EU/EEA membership
EU/EEA non-EU/EEA
N = 25 % N = 19 % p-value
National coordination
Existence of a written national strategy or plan that focuses exclusively or primarily on the prevention
and control of viral hepatitis and includes a surveillance component
6 24.0 6 31.6 0.412
Routine surveillance of viral hepatitis B and C
National surveillance system for acute HBV 25 100 18 94.7 0.432
National surveillance system for acute HCV 23 92.0 18 94.7 0.604
National surveillance system for chronic HBV 18 72.0 10 52.6 0.157
National surveillance system for chronic HCV 17 68.0 10 52.6 0.234
Standard case definitions for viral hepatitis infections 25 100 17 89.5 0.181
Regular hepatitis disease reports published 22 88.0 17 89.5 0.632
Hepatitis outbreaks required to be reported to the government and further investigated 23 92.0 19 100 0.317
Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other
surveillance activities for HBV and HBC
25 100 19 100 -
Other sources of strategic information and capacities for disease burden estimation
Deaths, including from hepatitis, reported to a central registry 25 100 17 89.5 0.181
Liver cancer cases registered nationally 22 88.0 13 68.4 0.122
Cases of HIV/hepatitis co-infection registered nationally 16 64.0 13 68.4 0.508
Viral hepatitis serosurveys conducted regularly 10 40.0 10 52.6 0.299
If yes, please specify the target populations:
- children 3 12.0 2 10.5 0.632
- general population 8 32.0 3 15.8 0.191
- people who inject drugs 6 24.0 6 31.6 0.412
- men who have sex with men 3 12.0 6 31.6 0.112
- other groups 7 28.0 10 52.6 0.089
All pregnant women screened for HBV 21 84.0 13 68.3 0.195
All donated blood (including family donations) screened for HBV 25 100 17a 94.4 0.419
All donated blood (including family donations) screened for HCV 25 100 18a 100 0.432
Areas in which Member States might want assistance from WHO
National plan 6 24.0 11 57.9 0.024
Surveillance 2 8.0 8 42.1 0.010
Burden estimation 6 24.0 9 47.4 0.097
aAndorra is not included in this calculation because Andorra does not have blood donation centres
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autopsy says “death from cirrhosis” but it is never
specified whether it was caused by hepatitis and what
kind. – National Association for Fighting Hepatitis –
Hepasist (Bulgaria)
Some respondents expressed concern about surveil-
lance systems not gathering information on treatment
uptake or treatment coverage.
In England noone knows how many people are treated
each year for HCV or HBV or what the outcomes
are, an extraordinary situation given the cost. –
The Hepatitis C Trust (United Kingdom)
The governmental structures receive partial information
on acute hepatitis, and the information is spread by
word-of-mouth. There are no follow-up data on what
happens to those diagnosed with acute hepatitis and
whether they receive treatment. – National Association
for Fighting Hepatitis – Hepasist (Bulgaria)
Discussion
This sub-analysis of surveillance-related data from the
WHO Global Policy Report on the Prevention and Con-
trol of Viral Hepatitis in WHO Member States demon-
strates that key surveillance components are in place in
most MS, suggesting that there is considerable potential
to acquire better data for decision-making. However,
substantial systemic shortcomings in hepatitis B and C
surveillance were reported throughout the WHO Euro-
pean Region. Survey findings for EU/EEA and non-EU/
EEA MS did not differ significantly for the most part,
suggesting that attention should be given to strengthen-
ing surveillance and strategic information systems across
the entire region.
While more than 90 % of MS reported conducting sur-
veillance for acute HBV and HCV infections, the surveil-
lance of chronic HBV and HCV infections was less
common. One reason for this may be that viral hepatitis
surveillance systems historically have focused on collec-
ting data on acute infections, primarily for the purpose
of identifying outbreaks. When WHO last published
recommendations on viral hepatitis surveillance in 2003,
the recommendations addressed surveillance of only acute
infection [25]. Another influential source of technical
guidance for the EU/EEA countries, ECDC, has only dis-
tinguished chronic infection with a revision of the EU case
definitions for hepatitis B and C surveillance in conjunc-
tion with the recent implementation of its enhanced sur-
veillance program. Data collected by the ECDC from the
31 countries it serves indicated that in 2013, only 17 coun-
tries were able to provide data on chronic HBV infection
[26], and 12 on chronic HCV infection [5]. The ECDCexperience, coupled with our own findings, suggests that
surveillance systems may not be evolving rapidly enough
to keep pace with recent developments in viral hepatitis
prevention and treatment. A greater orientation toward
chronic disease surveillance would contribute to efforts to
understand the hepatitis disease burden, assess the impact
of prevention and treatment efforts, and maximize the
impact of resources [27].
The classification of viral hepatitis infection as acute
versus chronic is a widely recognized challenge, espe-
cially for hepatitis C [28]. Data from our study indicate
that only 10 MS (23 %) have no hepatitis cases reported
as “undifferentiated” or “unclassified.” Some community
survey respondents’ comments provided further evidence
that distinguishing between acute and chronic hepatitis
might not be possible in their countries. While most
countries have case definitions, these vary across coun-
tries, making it difficult to compare data between coun-
tries. Progress has been made in the EU/EEA with the
2012 adoption of the revised EU case definitions [29], but
further work is needed in this area, including the devel-
opment of more accurate serological tests to better dis-
tinguish between acute and chronic HCV infection, and,
to a lesser extent, for HBV infection as well.
All responding countries stated that they have ad-
equate laboratory capacity nationally for outbreak inves-
tigations and other surveillance activities related to HBV
and HCV, an indication that there might be considerable
potential to improve and enhance viral hepatitis surveil-
lance, including electronic-based reporting from labora-
tories. The survey information, however, should be
regarded cautiously, as laboratory capacity at the central
level might differ substantially from laboratory capacity
at the regional and local levels.
The viral hepatitis disease burden can be assessed
more accurately when data from case reporting are con-
sidered in conjunction with data from other sources
such as death registries and disease registries. Almost all
responding MS in our study reported having central
death registries. Although these can potentially be used
to assess the proportions of deaths attributable to HBV
and HCV, the contribution of viral hepatitis to chronic
liver disease-related mortality may be underestimated if
death records are the only source of information [30, 31].
Since most deaths from HBV and HCV are due to com-
plications of liver disease rather than being directly attrib-
utable to the viral infection, viral hepatitis may not be
specified on the death certificate. Nonetheless, the useful-
ness of death registries in assessing the HBV and HCV
disease burden and evaluating the population-level im-
pact of treatment could be improved by linking such
registries to viral hepatitis diagnosis databases [32]. Dis-
ease registries are another potentially valuable source of
hepatitis information. In Europe, up to 15 % of primary
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HCV [33]. The majority of European countries respond-
ing to the WHO survey reported the existence of national
liver cancer registries, but the use of these data might be
problematic, as noted by a community survey respondent
from Poland. The feasibility of using liver cancer incidence
indicators associated with cancer registries for evaluating
the burden of chronic viral hepatitis infection has been
demonstrated [34], but the accurate contribution of
HBV and HCV infection to worldwide cancer trends is
not well defined [35].
Two-thirds (66 %) of responding MS reported having
national registries for HIV/viral hepatitis co-infection.
Such databases can be used as additional data sources
for chronic hepatitis surveillance and for identifying
high-prevalence groups that should be targeted for
screening [36]. In most jurisdictions globally, compre-
hensive HIV/AIDS surveillance has been in place for
many years. The ECDC and the WHO Regional Office
for Europe have effectively collaborated to jointly coord-
inate HIV/AIDS surveillance since 2008 for all 53 coun-
tries in the WHO European Region, although data on
HIV/viral hepatitis co-infection are not currently being
reported at the regional level [37]. The example of the
joint ECDC/WHO surveillance for HIV/AIDS may serve
as a useful model for strengthening viral hepatitis sur-
veillance at the regional level in the future.
Data from sero-surveys can make a unique contri-
bution to assessments of the burden of HBV and HCV
disease because sero-surveys identify the many asymp-
tomatic undiagnosed infections. Systematically repeated
sero-surveys can be considered a form of surveillance,
while single surveys provide a baseline measure of disease
prevalence. In addition, the results can be compared and
integrated with simultaneously collected epidemiologic
information or case reporting data [38]. Only 20 of 44
(45 %) responding study countries reported conducting
viral hepatitis sero-surveys regularly, and three other
countries (Croatia, Czech Republic and Latvia) reported
that they had conducted sero-surveys at least occa-
sionally. It is likely that the complexity and expense
of conducting sero-surveys are both factors limiting
their role in HBV and HCV surveillance in the WHO
European Region.
Many national surveillance programs may be able to
make good use of HBV and HCV seroprevalence data
that are already being recorded for two populations:
blood donors and pregnant women. Both populations
are subject to routine testing in accordance with health
care standards in many countries. In our study, almost
all responding MS reported having routine blood donor
screening for both HBV and HCV. In most cases, data
on the prevalence of HBV and HCV among blood do-
nors is readily available, thus providing a basis forestimating seroprevalence within the general popula-
tion. However, this is not a good proxy in most coun-
tries due to pre-screening selection of donors. HBV
and HCV seroprevalence data for pregnant women
may be more informative, but these data are not always
as readily available as data from blood transfusion
services because of less strictly regulated reporting
from maternity services to public health officials. Fur-
thermore, far fewer countries screen pregnant women
for HCV than HBV [6]. In our study, 77 % of respon-
ding MS reported having routine HBV screening for
pregnant women for HBV.
The lack of statistically significant differences between
EU/EEA countries and non-EU/EEA countries in regard
to the existence of chronic hepatitis surveillance and
national death and liver cancer registries was somewhat
surprising considering that EU/EEA countries generally
have higher income levels and greater health spending.
Twenty-two responding EU/EEA MS (88 %) were high-
income countries, while 15 non-EU/EEA respondents
(79 %) were low/middle income countries (p < 0.001), as
determined by World Bank 2012 country income classi-
fications. Also, EU/EEA countries might be expected to
benefit from the ECDC’s ongoing work to harmonize
and improve viral hepatitis surveillance in the region
that it serves. The finding that non-EU/EEA countries
were interested in potential assistance from WHO on
national planning and surveillance-related activities
could be partly explained by the fact that countries in
Eastern Europe and Central Asia traditionally have re-
ceived technical assistance from WHO, and thus may
be more likely to request it in the future. At the same
time, the finding indirectly suggests that their surveil-
lance systems may need greater attention than those
in EU/EEA countries.
Responses from the global community hepatitis policy
survey raise the following issues. First, some disagree-
ments with government information regarding national
surveillance policies and practices may indicate areas
in which governments misreported facts for the WHO
global policy survey. It is also possible that civil society
respondents may have questioned the accuracy of some
government information that was actually correct but was
not sufficiently communicated to all relevant stakeholders.
For example, civil society stakeholders in two countries
made statements questioning their governments’ asser-
tions that hepatitis disease reports are published. One ex-
planation may be that government agencies are compiling
and disseminating reports internally but not making
people outside of those agencies aware of their existence.
Beyond civil society respondents’ concerns about the
accuracy of what their governments reported, some of
their statements appear to offer informed opinions about
surveillance issues. While public health surveillance
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governments, findings from this study suggest that civil
society stakeholders in some settings may be able to make
important contributions to strengthening viral hepatitis
surveillance. Governments should consider this point as
they take action on the World Health Assembly’s 2014
viral hepatitis resolution, which, among other points,
urges MS “to promote the involvement of civil society
in all aspects of preventing, diagnosing and treating
viral hepatitis” [17].
In sum, virtually all responding countries in the WHO
European Region reported having viral hepatitis surveil-
lance systems in place, and there seem to be similar
challenges and opportunities for improvement across the
Region. However, it should be emphasized that the
WHO survey collected information about the existence
of policies and practices from national focal points but
did not assess the extent or quality of implementation.
Thus, it would be premature to draw conclusions about
the overall effectiveness or ineffectiveness of national
viral hepatitis surveillance systems based on the findings
of this study. Furthermore, before such systems can be
rigorously assessed, clarity is needed regarding the aims,
outcomes and capacities of surveillance. It may be that
many countries are achieving their stated viral hepatitis
surveillance aims even if they do not have all of the
components of what might be considered an ideal sur-
veillance system. It would be beneficial for the WHO
European Region as a whole to have a shared under-
standing of the specific ways in which surveillance is
intended to support effective responses to HBV and
HCV. This approach might entail recognizing, for ex-
ample, the importance of surveillance data for develop-
ing estimates of adverse outcomes of HBV and HCV,
such as those presented in the Global Burden of Disease
study [39], even while the surveillance data are under-
stood to provide an incomplete picture. It also might en-
tail adopting common definitions in order to avoid
confusion about issues such as those brought to light by
the Polish civil society respondent who asserted that,
what the government considers to be a surveillance sys-
tem, is merely a record of physicians’ voluntary reporting
of hepatitis cases. The prospect of large numbers of
people with chronic HCV gaining access to new treat-
ments with high cure rates in the coming years further
underscores the need for clarification about what na-
tional surveillance systems can contribute to tracking
the changing epidemiology of this disease.
Limitations
Our study suffers from a number of limitations in
addition to those already identified. First, although the
European Region had the second-highest response rate
to the WHO global policy survey among the six WHOregions, the absence of information from nine European
MS (13 %) limits the generalizability of study findings.
Other limitations relate to language and terminology.
Survey respondents were restricted to using five languages
(English, French, Spanish, Portuguese and Russian), and
this may have resulted in some respondents not fully
comprehending all of the survey questions. Furthermore,
some questions in the survey might have been understood
differently by respondents in different settings. Finally, the
data in the WHO Global Policy Report were submitted
by the identified focal points from MS, and researchers
did not verify the accuracy of the data prior to publication
of the report.
To some extent, the World Hepatitis Alliance’s civil
society survey provides useful complementary informa-
tion, although that survey was not designed to verify
governments’ responses to individual survey items. Also,
many respondents may not be fully qualified to have a
complete overview of the national surveillance system
and to assess whether responses to the WHO survey
were indeed correct. The civil society survey has add-
itional limitations as a robust source of data. Survey
responses were received from only about half of all
European countries, and some countries were repre-
sented by a single civil society respondent while others
were represented by multiple civil society respondents.
Furthermore, organizations that disagreed with the data
provided by governments may have been more likely to
respond to the survey than organizations that agreed.
These factors limit the extent to which generalizations
can be made on the basis of specific civil society survey
findings.
Conclusions
To conclude, our study indicates that there is high
overall capacity for robust HBV and HCV surveillance
throughout the WHO European Region, but that existing
surveillance systems have substantial weaknesses. Many
governments have surveillance systems in place, along
with laboratory capacity, and many governments are pro-
ducing surveillance reports on at least an occasional basis.
However, findings from the WHO policy survey and the
follow-up civil society survey point to shortcomings, such
as a lack of surveillance for chronic HBV and HCV dis-
ease, a lack of serosurveillance and an absence of mecha-
nisms for tracking treatment outcomes in many MS.
International organizations such as WHO and ECDC
have the potential to play an important role in supporting
country-level efforts to improve viral hepatitis surveillance
and developing a comprehensive framework for the col-
lection, analysis and use of strategic information. There is
an urgent need for European countries to strengthen their
surveillance programs to be able to monitor national
progress toward achieving ambitious global targets relating
Lazarus et al. Hepatology, Medicine and Policy  (2016) 1:3 Page 12 of 13to the elimination of viral hepatitis and to maximize the
population-level impact of advances in HBV and HCV
prevention and treatment.
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